The results of this systematic review and meta-analysis support the therapeutic potential of TKIs, including both SYK and BTK inhibitors, in managing adult ITP, particularly among individuals who have not responded adequately to or cannot tolerate standard first-line therapies. This evidence concerns the gene BTK and autoimmune thrombocytopenic purpura.